Platinum Prodrug Nanoparticles with COX-2 Inhibition Amplify Pyroptosis for Enhanced Chemotherapy and Immune Activation of Pancreatic Cancer

© 2023 Wiley-VCH GmbH..

Pyroptosis, an emerging mechanism of programmed cell death, holds great potential to trigger a robust antitumor immune response. Platinum-based chemotherapeutic agents can induce pyroptosis via caspase-3 activation. However, these agents also enhance cyclooxygenase-2 (COX-2) expression in tumor tissues, leading to drug resistance and immune evasion in pancreatic cancer and significantly limiting the effectiveness of chemotherapy-induced pyroptosis. Here, an amphiphilic polymer (denoted as PHDT-Pt-In) containing both indomethacin (In, a COX-2 inhibitor) and platinum(IV) prodrug (Pt(IV)) is developed, which is responsive to glutathione (GSH). This polymer self-assemble into nanoparticles (denoted as Pt-In NP) that can disintegrate in cancer cells due to the GSH responsiveness, releasing In to inhibit the COX-2 expression, hence overcoming the chemoresistance and amplifying cisplatin-induced pyroptosis. In a pancreatic cancer mouse model, Pt-In NP significantly inhibit tumor growth and elicit both innate and adaptive immune responses. Moreover, when combined with anti-programmed death ligand (α-PD-L1) treatment, Pt-In NP demonstrate the ability to completely suppress metastatic tumors, transforming "cold tumors" into "hot tumors". Overall, the sustained release of Pt(IV) and In from Pt-In NP amplifies platinum-drug-induced pyroptosis to elicit long-term immune responses, hence presenting a generalizable strategy for pancreatic cancer.

Medienart:

E-Artikel

Erscheinungsjahr:

2024

Erschienen:

2024

Enthalten in:

Zur Gesamtaufnahme - volume:36

Enthalten in:

Advanced materials (Deerfield Beach, Fla.) - 36(2024), 11 vom: 13. März, Seite e2310456

Sprache:

Englisch

Beteiligte Personen:

Yu, Bingzheng [VerfasserIn]
Wang, Yushu [VerfasserIn]
Bing, Tiejun [VerfasserIn]
Tang, Yujing [VerfasserIn]
Huang, Jia [VerfasserIn]
Xiao, Haihua [VerfasserIn]
Liu, Chaoyong [VerfasserIn]
Yu, Yingjie [VerfasserIn]

Links:

Volltext

Themen:

49DFR088MY
Chemotherapy
Cisplatin
Cyclooxygenase 2
EC 1.14.99.1
Immunotherapy
Journal Article
Platinum
Platinum drug
Polymers
Prodrugs
Pyroptosis
Q20Q21Q62J

Anmerkungen:

Date Completed 15.03.2024

Date Revised 15.03.2024

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1002/adma.202310456

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM365827118